CURRICULUM VITAE

A. PERSONAL INFORMATION

Name:	Marilyn Ader, Ph.D.
Business Address:	Diabetes and Obesity Research Institute Cedars-Sinai Medical Center 8700 Beverly Blvd., Thalians E106 Los Angeles, CA 90048
Business Phone:	(310) 967-2792
Business FAX:	(310) 967-3869
E-mail Address:	Marilyn.Ader@cshs.org

B. EDUCATION

Undergraduate College:	Utica College of Syracuse University, Utica, NY B.S. (Biology), 1980
Graduate School:	Kent State University, Kent, OH M.S. (Biological Sciences), 1982
	University of Southern California, Los Angeles, CA Ph.D. (Physiology and Biophysics), 1988
Honors and Awards:	American Diabetes Assoc. Postdoctoral Fellowship (mentor-based), 1988-1991
	NIH Predoctoral Training Fellowship (NIH T32-AG00093), 1985 to 1988
	NIH Predoctoral Training Fellowship (NIH T32-GM08017), 1982-1985
	First Prize, Young Investigators' Forum American Diabetes Assoc., Southern Calif. Affiliate
	Who's Who of American Colleges and Universities
	Biology Student of the Year; 1979-1980 Utica College of Syracuse University
	Dean's List; 1976-1980 Utica College of Syracuse University

C. PROFESSIONAL BACKGROUND

Academic Appointments:

Associate Professor, Department of Biomedical Sciences
Cedars-Sinai Medical Center
2013 to present

Associate Director, Diabetes and Obesity Research Institute
Cedars-Sinai Medical Center
2011 to present

Associate Professor, University of Southern California
Department of Physiology and Biophysics
1999-2011

Assistant Professor, University of Southern California
Department of Physiology and Biophysics
1991-1998

Visiting Professor of Physiology
LADSEB-CNR, Padova, Italy
1990

Acting Project Manager
University of Southern California, Department of Physiology and Biophysics
1989-1990

American Diabetes Association Postdoctoral Fellow
University of Southern California, Department of Physiology and Biophysics
1988-1991

Instructor, Cardiovascular, Pulmonary, & Digestive Physiology
University of Southern California, Physician's Assistant Program
1984

NIH Predoctoral Trainee
University of Southern California, Department of Physiology and Biophysics
1982-1988

Specific Teaching Responsibilities:

Grant-Writing Workshop for Post-doctoral Fellows
Cedars-Sinai Medical Center
Aug 2012 to Oct 2012

Lecturer in Physiology
University of Southern California, Physician's Assistant Program
1984

Lecturer and laboratory instructor in Human Physiology
Kent State University, Nursing program
1981-1982

Laboratory instructor in Microbiology
Kent State University, Biology Department
1980-1981

Laboratory instructor in Human Anatomy and Physiology
Utica College of Syracuse University, Biology Department
1979-1980

Specific Administrative Responsibilities:

National and International:

Member, Organizing Sub-Committee for In Vivo (Animals) Sessions, American Diabetes Association Annual Meeting
June 2015

Ad Hoc Member, NIH P01 Grant Review Panel (NIDDK)
December 2013

Ad Hoc Member, NIH Special Emphasis Panel (Endocrinology, Metabolism, Nutrition and Reproductive Sciences Section)
August 2013

Standing Member, NIH Study Section (IPOD: Integrative Physiology, Obesity, and Diabetes)
2008 to 2013

Co-Editor, *Obesity*
2011- 2012

Deputy Editor, *Obesity*
2007- 2011

Ad Hoc Member, NIH Study Section (NICHD: "Molecular Mechanisms of Adverse Metabolic Drug Effects in Children and Adolescents")
March 2011

Member, Publications Board, *Obesity*
2007- 2013

Ad Hoc Member, NIH Study Section (Center Grants in Schizophrenia; P50)
May 2009, November 2006, November 2005

Chair, NIH Study Section (PAR-08-160 RFA: "Metabolic Effects of Psychotropic Medications")
March 2009

Outside Ad Hoc Reviewer, Canadian Diabetes Association, Grant-in-Aid Program
March 2008

Ad Hoc Member, NIH Study Section (EMNR: Metabolism, Reproduction)
November 2007

Invited Reviewer, Transdisciplinary Research on Energetics and Cancer (TREC) Pilot Grant Application, University of Southern California
August 2007

Invited Grant Reviewer, Congressionally Directed Medical Research Program, Peer Reviewed Medical Research Program (Diabetes Pathogenesis Panel)
July 2006

Ad Hoc Member, NIH Study Section (IPOD: Integrative Physiology, Obesity, and Diabetes)
February 2006, February 2005

Invited Grant Reviewer, Metabolic Effects of Antipsychotics
BUPA Foundation
February 2006

Outside Ad Hoc Reviewer, Canadian Diabetes Association, Grant-in-Aid Program
March 2005

Ad Hoc Member, National Institutes of Aging Study Section (RFA on Dietary Restriction and Metabolism)
April 2001

Member, Organizing Sub-Committee for Metabolism, American Diabetes Association Annual Meeting
June 2006, July 2004

Member, Organizing Sub-Committee for In Vivo Animal Research Sessions, American Diabetes Association Annual Meeting
June 2005

Elected Member, Animal Care and Experimentation Committee
American Physiological Society
2003 – 2005

Organizer, Second International MINMOD Symposium (in conjunction with International. Diabetes Meeting, Washington, DC)
June 1991

Editorial Board, American Journal of Physiology (Endocrinology/Metabolism Section)
1998 – 2006

Journal Reviewer for:
American Journal of Pathology
American Journal of Physiology
American Journal of Psychiatry
Archives of General Psychiatry
Canadian Journal of Physiology and Pharmacology
Clinical Chemistry
CNS Drugs

Diabetes
Diabetes Care
Diabetologia
Endocrinology and Metabolism
European Neuropsychopharmacology
Growth Regulation
International Journal of Obesity
Journal of Applied Physiology
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Investigation
Journal of Diabetes and its Complications
Metabolism
Neurobiology of Aging
Neurophysiology of Aging
Neuropsychopharmacology
Obesity Research (now called "Obesity")
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Psychiatry Research
Schizophrenia Research

Local:

Member, Faculty Oversight Committee for Comparative Medicine
Cedars-Sinal Medical Center
2015-present

Director, Masters Degree Program
Cedars-Sinal Medical Center
2014-present

Member, Graduate (PhD, MS) Admissions Committee
Cedars-Sinal Medical Center
2012-present

Faculty Mentor, Clinical Scholars Grant Program
Cedars-Sinal Medical Center
2012-present

Member, Institutional Animal Care and Use Committee
Cedars-Sinal Medical Center
2012-present

Member, Animal Usage Advisory Committee
Cedars-Sinal Medical Center
2011-2013

Member, Institutional Animal Care and Use Committee
University of Southern California
1997-2011

Member, Animal Resources Committee, University of Southern California
2009, 2011

Representative, Public Responsibility in Medicine & Research (PRIM&R)
University of Southern California, Health Sciences Vivarium
2010, 2011

Invited Reviewer, Wright Foundation Grant Award, Univ. Southern Calif.
2006

Invited Reviewer, Transdisciplinary Research on Energetics and Cancer (TREC) Pilot Grant Application, University of Southern California
2006, 2007

Member, Emergency Operations Planning Committee
University of Southern California, Health Sciences Vivarium
1999-2002

Representative, Scientist's Center for Animal Welfare
University of Southern California, Health Sciences Vivarium
2000, 2002, 2007, 2010

Representative, National Association of Biomedical Research
University of Southern California, Health Sciences Vivarium
April 2000

Organizer, Symposium on Quantitative Approaches to Fuel Metabolism
University of Southern California
April 1992

Organizer, Annual Seminar Series for Department of Physiology and Biophysics, University of Southern California
1988-1989

Invited Lectures:

Invited speaker, Symposium on Insulin Clearance as a Regulated Process – Novel Mechanisms & Implications, annual meeting of the American Diabetes Assoc.
June 2015 (Boston, MA)

Invited interviewee, to discuss symposium lecture on insulin clearance, annual meeting of the American Diabetes Assoc.
June 2015 (Boston, MA)

Invited lecturer, Endocrine Research Seminar, Department of Medicine, Cedars-Sinai Medical Center
October 2013, November 2011

Invited lecturer, Adipogenic and Metabolic Effects of Antipsychotic Drugs
(Co-sponsored by NIH and University of Alabama at Birmingham)
July 2011 (Newark, NJ)

Invited lecturer, Diabetes Center Symposium, University of Southern California
November 2010 (Los Angeles, CA)

Invited speaker, Symposium on Atypical Antipsychotics and the Metabolic Syndrome, annual meeting of The Endocrine Society
June 2010 (San Diego, CA)

Invited speaker, Symposium on Antipsychotic Medications and Obesity, Obesity Society Annual Scientific Mtg
October 2008 (Phoenix, AZ)

Invited speaker, LivHome lecture series on Issues Facing Elderly Clients with Diabetes
March 2008 (Los Angeles, CA)

Invited speaker, Keystone Symposium on Neuronal Mechanisms Controlling Food Intake, Glucose Metabolism, and Body Weight
February 2008 (Banff, Alberta, Canada)

Invited participant, Solvay/Wyeth Pre-Clinical Consultant Board
October 2007 (Philadelphia, PA)

Invited speaker, Symposium on Management and Mechanisms of Antipsychotic-Associated Metabolic Disturbances, World Federation of Societies of Biological Psychiatry Annual Meeting
April 2007 (Santiago, Chile)

Invited participant, Cardiometabolic Health Working Group of The Joint Committee on Long-Term Management
April 2007 (Houston, TX)

Invited presenter, International Congress on Schizophrenia Research Annual Mtg
March 2007 (Colorado Springs, CO)

Invited lecturer, Astra Zeneca Toxicology Group
March 2007 (Wilmington, DE)

Invited speaker, Symposium on Translating Research on the Metabolic Effects of Antipsychotics into Public Health and Treatment Guidelines, American College of Neuropsychopharmacology Annual Mtg
December 2006 (Hollywood, FL)

Invited speaker, Training, Educating, and Mentoring Meeting of the USC Center for Transdisciplinary Research on Energetics and Cancer
December 2006 (Los Angeles, CA)

Invited speaker, Symposium on Knowledge to Practice: Nursing Role in Optimizing Metabolic and Cardiovascular Healthy of Psychiatric Patients, American Psychiatric Nurses Association Annual Mtg
October 2006 (Long Beach, CA)

Invited speaker, Diabetes Mellitus Interagency Coordinating Committee on Psychoactive Drugs and Type 2 Diabetes, National Institutes of Health
September 2006 (Bethesda, MD)

Invited lecturer, Post-Clinic Psychiatry Conference, Addenbrooke's Hospital, Cambridge University Teaching Hospitals Trust
September 2006 (Cambridge, United Kingdom)

Invited lecturer, Psychiatry and Metabolism Discussion Group, Warneford Hospital, Oxford University
September 2006 (Oxford, United Kingdom)

Invited speaker, Symposium on Metabolic Compensation, American Diabetes Association Annual Mtg
June 2006 (Washington, DC)

Invited speaker, Adipose and Metabolic Tissue Study Group, Boston University School of Medicine
March 2006 (Boston, MA)

Invited speaker, General Considerations for Metabolic Syndrome in Neuropsychiatry
February 2006 (Chicago, IL)

Invited speaker, Masterclass Meeting on Exploring the Cardiovascular Risk Burden in Psychiatric Disease, Royal College of Physicians of Ireland
December 2005 (Dublin, Ireland)

Invited speaker, CNS Scientific Team Science Day lecture, AstraZeneca
October 2005 (Chicago, IL)

Invited speaker, Antipsychotics, Mood Stabilizers and Metabolic Risk Conference, National Institutes of Mental Health (sponsored)
October 2005 (Washington University, St. Louis, MO)

Invited participation, Global Neuroscience Advisory Board Summit, Eli Lilly
September 2005 (Indianapolis, IN)

Invited speaker, Gerontology Research Conference, University of Maryland (hosted by Dr. Susan Fried)
May 2005 (Baltimore, MD)

Invited speaker, Obesity Research Center, Boston University School of Medicine (hosted by Dr. Barbara Corkey)
May 2005 (Boston, MA)

Invited symposium speaker, Am. Psychiatric Assoc. Annual Scientific Meeting
May 2005 (Atlanta, GA)

Invited speaker, West Coast College of Biological Psychiatry Annual Meeting
April 2005 (Pasadena, CA)

Invited speaker, Endocrine Grand Rounds, Cedars-Sinai Medical Center
February 2005 (Los Angeles, CA)

Invited speaker, USC Dept of Physiology & Biophysics Annual Colloquium
December 2004 (Los Angeles, CA)

Invited speaker, Collegium Internationale Neuro-Psychopharmacologicum Annual Scientific Meeting
June 2004 (Paris, France)

Invited speaker, N. Amer. Assoc. for the Study of Obesity Annual Scientific Mtg
October 2003 (Fort Lauderdale, FL)

Invited speaker, 2nd International Workshop on Insulin Resistance
February 2002 (San Diego, CA)

Invited speaker, NIH/NIA Symposium on Diabetes and Aging
February 2001 (Bethesda, MD)

Invited speaker, North American Association for the Study of Obesity (NAASO) Annual Scientific Meeting
October 2001 (Quebec City, Quebec, Canada)

Invited speaker, USC Diabetes Research Center Colloquium
April 2000 (Los Angeles, CA)

Invited speaker, USC Department of Animal Resources Staff Lecture
April 2000 (Los Angeles, CA)

Invited speaker, Cedars Sinai Endocrine Research Seminar
October 1999 (Los Angeles, CA)

Invited CME lecturer, City of Hope Diabetes Research Center
March 1999 (Duarte, CA)

Invited Meet the Professor Lecture, European Assoc. for the Study of Diabetes
September 1998 (Barcelona, Spain)

Invited CME lecturer, City of Hope Diabetes Research Center
September 1997 (Duarte, CA)

Invited speaker, Fourth International MINMOD Symposium
July 1997 (Copenhagen, Denmark)

Invited speaker, Ohio State University, Department of Medicine
March 1996 (Columbus, OH)

Invited CME lecturer, City of Hope Diabetes Research Center
May 1995 (Duarte, CA)

Invited CME lecturer, City of Hope Diabetes Research Center
December 1993 (Duarte, CA)

Invited speaker, LADSEB-CNR
September 1993 (Padova, Italy)

Invited speaker, Second International MINMOD Symposium
June 1991 (Washington, DC)

Invited speaker, IMEKO Conference "Measurement in Clinical Medicine"
August 1990 (Sopron, Hungary)

Invited speaker, University of Genova, Department of Medicine
August 1990 (Genova, Italy)

Invited speaker, NIH, Dept. of Experimental Diabetes, Metabolism, & Nutrition
May 1989 (Bethesda, MD)

Invited speaker, Southern California Diabetes Research Symposium
December 1988 (Los Angeles, CA)

Invited speaker, George Washington University, Department of Physiology
May 1988 (Washington, DC)

Invited speaker, Fifth Annual All-Ohio Student Conference on Aging
April 1982 (Columbus, OH)

Invited Scientific Session Chairperson:

Session Chair, American Diabetes Association Annual Scientific Meeting (Session: Central Nervous System and Enteric Hormones Regulate Cellular Metabolism)
June 2015 (Boston, MA)

Oral Abstract Session Chair, Endocrine Society (Session: Linking Obesity and Insulin Resistance)
May 2010 (San Diego, CA)

Colloquium Chair, American Diabetes Association Annual Scientific Program (Session: Endothelial Dysfunction: The Cart or the Horse for Insulin Resistance)
June 2005 (San Diego, CA)

Oral Abstract Session Chair, Endocrine Society (Session: Neuroendocrine Aspects of Aging and Gut Regulatory Peptides)
June 2002 (San Francisco, CA)

Poster Session Chair, European Association for the Study of Diabetes Annual Meetings (Session: Glucose Effectiveness)
September 2000 (Jerusalem, Israel)

Colloquium Chair, American Diabetes Association Annual Scientific Program (Session: Rate-Limiting Steps in Insulin Action)
June 2000 (San Antonio, TX)

Sesssion Chair, International Diabetes Federation Annual Meeting (Session: Endogenous Glucose Production)
July 1997 (Helsinki, Finland)

Session Chair, American Society for Clinical Research (Session: Metabolism & Diabetes)
February 1996 (Carmel, CA)

Session Chair, American Diabetes Association Annual Scientific Meeting (Session: Clinical Physiology)
June 1988 (New Orleans, LA)

Invited Scientific Reviewer, American Diabetes Association Annual Scientific Program (Session: In Vivo Animal Research)
June 2000 (San Antonio, TX)

International Diabetes Federation meetings (Session: Metabolism)
July 1997 (Helsinki, Finland)

D. SOCIETY MEMBERSHIPS

National and International:

American Diabetes Association
American Physiological Society
Endocrine Society
The Obesity Society
Public Responsibility in Medicine and Research (PRIM&R)

E. CONSULTANTSHIPS

Janssen Pharmaceutica (2002-2003)
AstraZeneca (2005; invited speaker only)
Eli Lilly (2005)
Solvay/Wyeth (2007)

F. RESEARCH FUNDING

Marilyn Ader, Principal Investigator:

Islet Transplant Program
Islet Sheet Medical and Hanuman Foundation
2/15/11 to 12/31/12

Metabolic Effects of Atypical Antipsychotics (parent grant: DK68596)
ARRA: Administrative Supplement (NOT-OD-09-056 Recovery Act)
National Institutes of Health
1/1/10 to 3/31/10

Metabolic Effects of Atypical Antipsychotics (DK68596)
National Institutes of Health
5/1/05 to 4/30/10

Mechanisms of the Glucose Intolerance of Aging (AG15111)
National Institutes of Health
12/1/98 to 11/30/02

Etiology of the Glucose Effectiveness of Aging (AG00544)
National Institutes of Aging
2/1/92 to 12/31/96

Marilyn Ader, co-Principal Investigator:

Quantitation of Factors Regulating Glucose Tolerance (DK29867)
R.N. Bergman, Ph.D., Principal Investigator
National Institutes of Health
7/1/15 to 6/30/20

Quantitative Studies of Metabolic Organ Dynamics (DK27619)
R.N. Bergman, Ph.D., Principal Investigator
National Institutes of Health
4/1/07 to 3/31/16

Effects of Rimonabant on the Canine Model of Fat-Fed Obesity
R.N. Bergman, Ph.D., Principal Investigator
Sanofi-Aventis
11/1/05 to 10/31/08

Metabolic Effects of Atypical Antipsychotics
R.N. Bergman, Ph.D., Principal Investigator
Janssen Pharmaceutica
9/1/02 to 8/30/04

Histoenzymatic Analysis of AMP Deaminase Alterations During the Normal Aging Process of Skeletal Muscle Tissues in the Syrian Hamster, Used as a Model for Human Aging
J.J. Gilloteaux, Ph.D., co-recipient
Awarded by the Geriatric Medicine/Gerontology Advisory Committee
Northeastern Ohio Universities College of Medicine
1/82-6/82

Proposal for the Development of a Module of the Physiology of Aging
N.F. Paradise, Ph.D., co-recipient
Awarded by the Geriatric Medicine/Gerontology Advisory Committee
Northeastern Ohio Universities College of Medicine
6/81-8/81

G. BIBLIOGRAPHY

1. Bergman RN, M Ader, DT Finegood, and G Pacini. Extrapancreatic effect of somatostatin infusion to increase glucose clearance. *Am J Physiol* 247:E370-E379, 1984.
2. Bergman RN, DT Finegood, and M Ader. Assessment of insulin sensitivity in vivo. *Endocr Rev* 6:45-86, 1984.
3. Ader M, Y Yang, G Pacini, and RN Bergman. Importance of glucose *per se* to intravenous glucose tolerance: comparison of the minimal model prediction with direct measurements. *Diabetes* 34:1092-1103, 1985.
4. Ader M and RN Bergman. Insulin sensitivity in the intact organism. In: *Bailliere's Clinics in Endocrinology and Metabolism. Techniques for Metabolic Investigation in Man*. Alberti, KGMM, PD Home, and R Taylor (eds), Bailliere Tindall, London, 1(4):879-910, 1987.

5. Ader M, T Agajanian, DT Finegood, and RN Bergman. Recombinant DNA-derived 22K- and 20K-human growth hormone generate equivalent diabetogenic effects during chronic infusion in dogs. *Endocrinology* 120:725-731, 1987.

6. Yang YJ, ID Hope, M Ader, and RN Bergman. Insulin transport across capillaries is rate limiting for insulin action in dogs. *J Clin Invest* 84:1620-1628, 1989.

7. Bergman RN, ID Hope, YJ Yang, RM Watanabe, MA Meador, JH Youn, and M Ader. Assessment of insulin sensitivity in vivo: a critical review. *Diab Metab Rev* 5:411-429, 1989.

8. Ader M and RN Bergman. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. *Am J Physiol* 258:E1020-E1032, 1990.

9. Bergman RN, YJ Yang, ID Hope, and M Ader. The role of the transcapillary insulin transport in the efficiency of insulin action: studies with glucose clamps and the minimal model. *Horm Metab Res* 24:49-56, 1990.

10. Yang YJ, ID Hope, M Ader, RA Poulin, and RN Bergman. Dose response relationship between lymph insulin and glucose uptake reveals enhanced insulin sensitivity of peripheral tissues. *Diabetes* 41:241-252, 1992.

11. Lee A, M Ader, GA Bray, and RN Bergman. Diurnal variation in glucose tolerance: cyclic suppression of insulin action and insulin secretion in normal weight, but not obese subjects. *Diabetes* 41:750-759, 1992.

12. Bergman RN, DC Bradley, and M Ader. On insulin action in vivo: the single gateway hypothesis. *Adv Exp Biol Med* 334:181-198, 1993.

13. Bergman RN and M Ader. Concepts emerging from the minimal model approach. In: *Frontiers in Diabetes, vol. 12: Current Topics in Diabetes Research*. F Belfiore, RN Bergman, and GM Molinatti, eds., Karger 12:39-65, 1993.

14. Yang YJ, ID Hope, M Ader, and RN Bergman. Importance of transcapillary insulin transport to dynamics of insulin action following intravenous glucose. *Am J Physiol* 266:E17-E25, 1994.

15. Poulin RA, GM Steil, DM Moore, M Ader, and RN Bergman. Dynamics of glucose production and uptake are more closely related to insulin in hindlimb lymph than in thoracic duct lymph. *Diabetes* 43:180-190, 1994.

16. Bergman RN and M Ader. Pathogenesis of NIDDM. In: *Diabetes (Nestle Nutrition Workshop Series)*. RM Cowett, ed. Vevey/Raven Press 35:99-117, 1995.

17. Steil GM, M Ader, DM Moore, K Rebrin, and RN Bergman. Transendothelial insulin transport is not saturable in vivo: no evidence for a receptor-mediated process. *J Clin Invest* 97:1497-1503, 1996.

18. Best JD, SE Kahn, M Ader, RM Watanabe, T-C Ni, and RN Bergman. Role of glucose effectiveness in the determination of glucose tolerance. *Diab Care* 19:1018-1030, 1996.

19. Bergman RN, R Watanabe, K Rebrin, M Ader, and G Steil. Toward an integrated phenotype in pre-NIDDM. *Diab Med* 13 (suppl 6):S67-S77, 1996.

20. Bergman RN, T-C Ni, and M Ader. Glucose effectiveness. In: *Clinical Research in Diabetes*. Draznin B and RA Rizza, eds. Humana Press, Totowa, NJ, 1996.

21. Ader M. Physiologic principles underlying glucose effectiveness. In: *The Minimal Model Approach and Determinants of Glucose Tolerance*. Pennington Center Nutrition Series, Vol. 7. RN Bergman and JC Lovejoy, eds. LSU Press, Baton Rouge, LA, 1997.

22. Ni T-C, M Ader, and RN Bergman. Reassessment of glucose effectiveness and insulin sensitivity from minimal model analysis: a theoretical evaluation of the single compartment distribution assumption. *Diabetes* 46:1813-1821, 1997.

23. Ader M, T-C Ni, and RN Bergman. Glucose effectiveness assessed under dynamic and steady state conditions: comparability of uptake versus production components. *J Clin Invest* 99:1187-1199, 1997.

24. Ader M, JM Richey, and RN Bergman. Evidence for direct action of alloxan to induce insulin resistance at the cellular level. *Diabetologia* 41:1327-1336, 1998.

25. Getty L, M Hamilton-Wessler, M Ader, M Dea, and RN Bergman. Biphasic insulin secretion during IVGTT promotes optimal interstitial insulin profile. *Diabetes* 47:1941-1947, 1998.

26. Hamilton-Wessler M, M Ader, M Dea, D Moore, PN Jorgensen, J Markussen, and RN Bergman. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. *Diabetologia* 42:1254-1263, 1999.

27. Richey JM, M Ader, D Moore, and RN Bergman. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. *Am J Physiol* 277:E920-E926, 1999.

28. Bergman RN and M Ader (INVITED REVIEW). Free fatty acids and pathogenesis of Type 2 diabetes mellitus. *Trends Endocrinol Metab* 11:351-356, 2000.

29. Dea MK, GW Van Citters, M Ader, SD Mittelman, AL Sunehag, and RN Bergman. Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. *Diabetes* 49:2087-2093, 2000.

30. Bergman RN, M Ader, K Huecking, and GW Van Citters. Accurate assessment of β-cell function: the hyperbolic correction. *Diabetes* 51:S212-S220, 2002.

31. Hamilton-Wessler M, M Ader, MK Dea, D Moore, M Loftager, J Markussen, and RN Bergman. Mode of transcapillary transport of insulin & insulin analog, NN304, in dog hindlimb: evidence for passive diffusion. *Diabetes* 51:574-582, 2002.

32. Dea MK, M Hamilton-Wessler, M Ader, D Moore, L Schaffer, M Loftager, A Volund, and RN Bergman. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. *Diabetes* 51:762-769, 2002.

33. Bergman RN, SP Kim, M Ellmerer, K Huecking, L Getty, M Kabir, V Ionut, J Richey, S Mittelman, G Van Citters, and M Ader. Physiological basis of the metabolic syndrome. In: *Progress in Obesity Research*. Vol. 9. G Medeiros-Neto, A Halpern, and C Bouchard, eds. John Libbey Eurotext Ltd, pp 653-656, 2003

34. M Ader, SP Kim, KJ Catalano, V Ionut, K Hucking, JM Richey, M Kabir, and RN Bergman. Metabolic dysregulation with atypical antipsychotics occur in the absence of

underlying disease: placebo controlled study of olanzapine and risperidone in dogs. *Diabetes* 54:862-871, 2005.

35. Catalano KJ, R Bergman, and M Ader. Increased susceptibility to insulin resistance associated with intra-abdominal obesity in old rats. *Obes Res* 13:11-20, 2005.

36. Bergman RN and M Ader. Atypical antipsychotics and glucose homeostasis. *J Clin Psychiatry* 66:504-514, 2005.

37. Bergman RN, SP Kim, KJ Catalano, IR Hsu, JD Chiu, M Kabir, K Hucking, and M Ader. Why visceral fat is bad: mechanisms of the metabolic syndrome. *Obesity* 14 (suppl) 16S-19S, 2006.

38. Bergman RN, SP Kim, IR Hsu, KJ Catalano, JD Chiu, M Kabir, JM Richey, and M Ader. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. *Am J Med* 120 (suppl 2A):S3-S8, 2007.

39. Bergman RN, SP Kim, KJ Catalano, IR Hsu, JD Chiu, M Kabir, K Hucking, and M Ader. Why visceral fat is bad: mechanisms of the metabolic syndrome. *Obesity* 14 (suppl) 16S-19S, 2006.

40. Bergman RN and M Ader. Midterm grades. *Obesity* 16:1479-1480, 2008.

41. Ader M, WT Garvey, LS Phillips, CB Nemeroff, GM Gharabawi, RA Mahmoud, AJ Greenspan, SA Berry, DL Musselman, JD Morein, Y Zhu, L Mao, and RN Bergman. Ethnic heterogeneity in glucoregulatory function during atypical antipsychotic therapy in subjects with schizophrenia. *J Psychiatric Research* 42:1076-1085, 2008.

42. Bergman RN, M Ader, and A Must. Conflict of interest policy for editors of *Obesity. Obesity* 17:1655-1656, 2009.

43. Soleimanpour SA, B Hirshberg, DJ Bunnell, AE Sumner, M Ader, AT Remaley, KI Rother, MR Rickels, and DM Harlan. Metabolic function of a suboptimal transplanted islet mass in non-human primates on rapamycin monotherapy. *Cell Transplantation* 21:1297-1304, 2012.

44. D Stefanovski, JH Youn, RM Watanabe, M Ader, V Ionut, AU Jackson, M Boehnke, FS Collins, M Rees, and RN Bergman. Estimating hepatic glucokinase activity using a simple model of lactate kinetics. *Diab Care* 35:115-1020, 2012.

45. Ader M, D Stefanovski, SP Kim, JM Richey, V Ionut, KJ Catalano, K Hucking, M Ellmerer, GW Van Citters, IR Hsu, JD Chiu, OO Woolcott, LN Harrison, D Zheng, M Lottati, CM Kolka, V Mooradian, J Dittmann, S Yae, H Liu, AVB Castro, M Kabir, and RN Bergman. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. *Obesity* 22:1238-1245, 2014.

46. Gohlke JM, EJ Dhurandhar, CU Correll, EH Morrato, JW Newcomer, G Remington, HA Nasrallah, G Nicol, Adipogenic and Metabolic Effects of APDs Conference Speakers [including M Ader], and DB Allison. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. *Frontiers in Psychiatry* 3:1-12, 2012.

47. Ader M, D Stefanovski, JM Richey, SP Kim, CM Kolka, V Ionut, M Kabir, and RN Bergman. Failure of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) to detect marked diet-induced insulin resistance in dogs. *Diabetes* 63:1914-1919, 2014

48. Bergman RN and M Ader. Measuring insulin action in vivo. *In:* International Textbook of Diabetes Mellitus, 4th Ed. (Section 3: "Normal Physiology of Insulin Action"), Ferrannini E, P Zimmet, R DeFronzo, and G Alberti (eds), Wiley-Blackwell, 2015.

49. Woolcott OO, M Ader, and RN Bergman. Glucose homeostasis during short-term and prolonged exposure to high altitudes. Endocr Rev 36:149-173, 2015

50. Castro AV, OO Woolcott, MS Iyer, M Kabir, V Ionut, D Stefanovski, CM Kolka, LS Szczepaniak, EW Szczepaniak, I Asare-Bediako, RL Paszkiewicz, JL Broussard, SP Kim, EL Kirkman, HC Rios, H Mkrtchyan, Q Wu, M Ader, and RN Bergman. Increase in visceral fat per se does not induce insulin resistance in the canine model. Obesity 23:105-111, 2015.